M. Refici

AntitumorActivity of Orally Bioavailable Farnesyltransferase Inhibitor , ABT-100 , Is Mediated byAntiproliferative , Proapoptotic , and Antiangiogenic Effects in XenograftModels

S. Rosenberg, H. Sham, J. O'Connor, 2005 .

Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models

Haiying Zhang, N. Lin, H. Sham, 2005, Clinical Cancer Research.

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

C. Tse, S. Fesik, S. Rosenberg, 2008, Clinical Cancer Research.

Fcγ-receptor signaling augments the LPS-stimulated increase in serum tumor necrosis factor-α levels

B. Arulanandam, D. Metzger, M. Lennartz, 2001 .

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

C. Tse, S. Fesik, S. Chemburkar, 2008, Molecular Cancer Therapeutics.

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

Saul H. Rosenberg, Stephen W. Fesik, C. Tse, 2010, Cancer Chemotherapy and Pharmacology.

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

S. Fesik, S. Chemburkar, S. Rosenberg, 2008, Molecular Cancer Therapeutics.